DK3679946T3 - Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin - Google Patents

Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin Download PDF

Info

Publication number: DK3679946T3
Authority: DK; Denmark
Prior art keywords: tryptophan; tyrosine; formulation stabilized; neurotoxin formulation; liquid
Prior art date: 2016-05-27

Application number

DK20152386.7T

Other languages

English (en)

Inventor

Anders Jarstad

Anna Friis

Ulf Stahl

Ann Gurell

Barbro Agren

Emilia Edstrom

Andrew Pickett

Original Assignee

Ipsen Biopharm Ltd

Galderma Holding SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-27

Filing date

2017-05-26

Publication date

2022-02-07

2017-05-26 Application filed by Ipsen Biopharm Ltd, Galderma Holding SA filed Critical Ipsen Biopharm Ltd

2022-02-07 Application granted granted Critical

2022-02-07 Publication of DK3679946T3 publication Critical patent/DK3679946T3/da

Links

QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
101710138657 Neurotoxin Proteins 0.000 title 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000007788 liquid Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000002581 neurotoxin Substances 0.000 title 1
231100000618 neurotoxin Toxicity 0.000 title 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Birds (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Gerontology & Geriatric Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)

DK20152386.7T 2016-05-27 2017-05-26 Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin DK3679946T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2016062085		2016-05-27
EP17728095.5A EP3463432B1 (en)	2016-05-27	2017-05-26	Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Publications (1)

Publication Number	Publication Date
DK3679946T3 true DK3679946T3 (da)	2022-02-07

Family

ID=56289455

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK20152386.7T DK3679946T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
DK17728095.5T DK3463432T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK17728095.5T DK3463432T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin

Country Status (30)

Country	Link
US (4)	US20190183988A1 (da)
EP (3)	EP3463432B1 (da)
JP (1)	JP7053498B2 (da)
KR (2)	KR102399451B1 (da)
CN (2)	CN109562148A (da)
AR (1)	AR108631A1 (da)
AU (1)	AU2017270359B2 (da)
BR (1)	BR112018074311A2 (da)
CA (1)	CA3025437A1 (da)
CY (2)	CY1124237T1 (da)
DK (2)	DK3679946T3 (da)
EA (1)	EA038124B1 (da)
ES (2)	ES2846350T3 (da)
GE (1)	GEP20207139B (da)
HR (2)	HRP20220024T1 (da)
HU (2)	HUE052023T2 (da)
IL (2)	IL285190B (da)
LT (2)	LT3679946T (da)
MX (1)	MX2018014631A (da)
PL (2)	PL3463432T3 (da)
PT (2)	PT3463432T (da)
RS (2)	RS61340B1 (da)
RU (1)	RU2741497C9 (da)
SA (1)	SA518400513B1 (da)
SG (1)	SG11201810561YA (da)
SI (2)	SI3679946T1 (da)
TW (1)	TWI777955B (da)
UA (1)	UA123679C2 (da)
WO (1)	WO2017203038A1 (da)
ZA (1)	ZA201807904B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
DK3332805T3 (da)	2008-12-31	2022-05-16	Revance Therapeutics Inc	Injicerbare botulinumtoksinformuleringer
BRPI1015938A2 (pt)	2009-06-25	2016-09-27	Revance Therapeutics Inc	formulações da toxina botulínica livre de albumina
US9480731B2 (en)	2013-12-12	2016-11-01	Medy-Tox, Inc.	Long lasting effect of new botulinum toxin formulations
KR20240023684A (ko)	2016-09-13	2024-02-22	알레간 인코포레이티드	안정화된 비단백질 클로스트리듐 독소 조성물
WO2019126502A1 (en) *	2017-12-20	2019-06-27	Allergan, Inc.	Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
AR119101A1 (es) *	2019-06-07	2021-11-24	Nestle Skin Health S A	Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
TW202333767A (zh) *	2022-01-14	2023-09-01	英商益普生生物製藥有限公司	中度至極重度眉間紋及眼角外紋之治療
AR128514A1 (es)	2022-02-15	2024-05-15	Merz Pharma Gmbh & Co Kgaa	Formulación líquida de toxina botulínica y su uso

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI240627B (en) *	1996-04-26	2005-10-01	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
PT1398038E (pt)	2000-02-08	2007-02-28	Allergan Inc	Composições farmacêuticas de toxina botulínica
EP1260230A4 (en)	2000-02-29	2008-08-06	Chugai Pharmaceutical Co Ltd	LONG-TERM STABILIZED PREPARATIONS
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors
DE10333317A1 (de)	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en)	2004-07-12	2006-01-18	Ipsen Ltd	Botulinum neurotoxin composition
KR100852822B1 (ko) *	2004-07-26	2008-08-18	메르츠 파마 게엠베하 운트 코. 카가아	보툴리눔 신경독소를 포함하는 치료 조성물
EP1778279B1 (en)	2004-08-04	2014-12-03	Ipsen Biopharm Limited	Pharmaceutical composition containing botulinum neurotoxin a2
US20080220021A1 (en)	2005-02-14	2008-09-11	Pankaj Modi	Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr)	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
JP5259710B2 (ja) *	2007-07-10	2013-08-07	メディ‐トックス、インク．	ボツリヌス毒素の安定性が改善された薬学的液状組成物
US9107815B2 (en) *	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
EP2715355B1 (en)	2011-06-01	2017-03-08	Biomadison, Inc.	Non-fret botulinum assay
SI2761065T1 (en)	2011-09-29	2018-02-28	Cellsnap, Llc	Ingredients and procedures for toxicity testing
KR101357999B1 (ko) *	2012-03-20	2014-02-03	함종욱	보툴리눔 에이형 독소의 액상제품
WO2015044416A1 (en)	2013-09-30	2015-04-02	Galderma S.A.	Prostate cancer treatment
GB201407525D0 (en) *	2014-04-29	2014-06-11	Syntaxin Ltd	Manufacture of recombinant clostridium botulinum neurotoxins

2017
- 2017-05-26 US US16/304,986 patent/US20190183988A1/en not_active Abandoned
- 2017-05-26 LT LTEP20152386.7T patent/LT3679946T/lt unknown
- 2017-05-26 HR HRP20220024TT patent/HRP20220024T1/hr unknown
- 2017-05-26 KR KR1020187037095A patent/KR102399451B1/ko active IP Right Grant
- 2017-05-26 PT PT177280955T patent/PT3463432T/pt unknown
- 2017-05-26 AU AU2017270359A patent/AU2017270359B2/en active Active
- 2017-05-26 JP JP2018562171A patent/JP7053498B2/ja active Active
- 2017-05-26 MX MX2018014631A patent/MX2018014631A/es unknown
- 2017-05-26 HU HUE17728095A patent/HUE052023T2/hu unknown
- 2017-05-26 HU HUE20152386A patent/HUE057640T2/hu unknown
- 2017-05-26 GE GEAP201714939A patent/GEP20207139B/en unknown
- 2017-05-26 ES ES17728095T patent/ES2846350T3/es active Active
- 2017-05-26 CA CA3025437A patent/CA3025437A1/en active Pending
- 2017-05-26 UA UAA201811606A patent/UA123679C2/uk unknown
- 2017-05-26 DK DK20152386.7T patent/DK3679946T3/da active
- 2017-05-26 RU RU2018142149A patent/RU2741497C9/ru active
- 2017-05-26 EP EP17728095.5A patent/EP3463432B1/en active Active
- 2017-05-26 DK DK17728095.5T patent/DK3463432T3/da active
- 2017-05-26 LT LTEP17728095.5T patent/LT3463432T/lt unknown
- 2017-05-26 KR KR1020227012437A patent/KR102423739B1/ko active IP Right Grant
- 2017-05-26 CN CN201780044565.1A patent/CN109562148A/zh active Pending
- 2017-05-26 TW TW106117499A patent/TWI777955B/zh active
- 2017-05-26 CN CN202010742639.2A patent/CN111701010B/zh active Active
- 2017-05-26 EP EP21211390.6A patent/EP4026532A1/en active Pending
- 2017-05-26 EA EA201892493A patent/EA038124B1/ru unknown
- 2017-05-26 SI SI201731069T patent/SI3679946T1/sl unknown
- 2017-05-26 SG SG11201810561YA patent/SG11201810561YA/en unknown
- 2017-05-26 ES ES20152386T patent/ES2911124T3/es active Active
- 2017-05-26 PL PL17728095T patent/PL3463432T3/pl unknown
- 2017-05-26 SI SI201730582T patent/SI3463432T1/sl unknown
- 2017-05-26 PT PT201523867T patent/PT3679946T/pt unknown
- 2017-05-26 RS RS20201596A patent/RS61340B1/sr unknown
- 2017-05-26 RS RS20220045A patent/RS62832B1/sr unknown
- 2017-05-26 IL IL285190A patent/IL285190B/en unknown
- 2017-05-26 WO PCT/EP2017/062785 patent/WO2017203038A1/en unknown
- 2017-05-26 BR BR112018074311A patent/BR112018074311A2/pt unknown
- 2017-05-26 EP EP20152386.7A patent/EP3679946B1/en active Active
- 2017-05-26 PL PL20152386T patent/PL3679946T3/pl unknown
- 2017-05-29 AR ARP170101464A patent/AR108631A1/es unknown
2018
- 2018-11-21 IL IL263173A patent/IL263173B/en unknown
- 2018-11-22 ZA ZA2018/07904A patent/ZA201807904B/en unknown
- 2018-11-26 SA SA518400513A patent/SA518400513B1/ar unknown
2020
- 2020-12-28 HR HRP20202070TT patent/HRP20202070T1/hr unknown
2021
- 2021-01-05 CY CY20211100001T patent/CY1124237T1/el unknown
- 2021-06-28 US US17/304,888 patent/US20230190892A9/en not_active Abandoned
2022
- 2022-01-25 CY CY20221100057T patent/CY1124916T1/el unknown
2023
- 2023-02-24 US US18/173,991 patent/US20230181702A1/en not_active Abandoned
- 2023-09-28 US US18/476,731 patent/US20240050539A1/en active Pending

Also Published As

Publication number	Publication date
ES2911124T3 (es)	2022-05-17
SG11201810561YA (en)	2018-12-28
CA3025437A1 (en)	2017-11-30
US20210330765A1 (en)	2021-10-28
SI3679946T1 (sl)	2022-04-29
JP2019517481A (ja)	2019-06-24
EP3463432B1 (en)	2020-10-07
WO2017203038A1 (en)	2017-11-30
LT3679946T (lt)	2022-02-10
RS62832B1 (sr)	2022-02-28
TWI777955B (zh)	2022-09-21
SA518400513B1 (ar)	2022-11-03
PT3463432T (pt)	2021-01-12
BR112018074311A2 (pt)	2019-10-01
CN109562148A (zh)	2019-04-02
CN111701010B (zh)	2023-09-26
US20230190892A9 (en)	2023-06-22
UA123679C2 (uk)	2021-05-12
EA038124B1 (ru)	2021-07-09
JP7053498B2 (ja)	2022-04-12
IL263173A (en)	2018-12-31
LT3463432T (lt)	2021-01-25
RU2741497C9 (ru)	2021-04-30
RS61340B1 (sr)	2021-02-26
AU2017270359A1 (en)	2018-12-13
SI3463432T1 (sl)	2021-02-26
EP3679946B1 (en)	2022-01-05
EP3679946A1 (en)	2020-07-15
US20240050539A1 (en)	2024-02-15
IL263173B (en)	2021-08-31
HRP20220024T1 (hr)	2022-04-01
ES2846350T3 (es)	2021-07-28
PL3679946T3 (pl)	2022-05-30
CN111701010A (zh)	2020-09-25
EA201892493A1 (ru)	2019-04-30
HUE057640T2 (hu)	2022-05-28
PT3679946T (pt)	2022-01-14
US20230181702A1 (en)	2023-06-15
EP4026532A1 (en)	2022-07-13
IL285190A (en)	2021-08-31
KR20190022548A (ko)	2019-03-06
HRP20202070T1 (hr)	2021-02-19
HUE052023T2 (hu)	2021-04-28
EP3463432A1 (en)	2019-04-10
MX2018014631A (es)	2019-06-12
GEP20207139B (en)	2020-07-27
KR102399451B1 (ko)	2022-05-23
AU2017270359B2 (en)	2023-09-21
IL285190B (en)	2022-07-01
RU2741497C2 (ru)	2021-01-26
US20190183988A1 (en)	2019-06-20
CY1124916T1 (el)	2023-01-05
KR20220054887A (ko)	2022-05-03
TW201742632A (zh)	2017-12-16
RU2018142149A (ru)	2020-06-29
ZA201807904B (en)	2020-05-27
AR108631A1 (es)	2018-09-12
CY1124237T1 (el)	2022-07-22
KR102423739B1 (ko)	2022-07-21
PL3463432T3 (pl)	2021-04-19
DK3463432T3 (da)	2021-01-04
RU2018142149A3 (da)	2020-07-23

Publication	Publication Date	Title
DK3679946T3 (da)	2022-02-07	Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin
DK3212208T3 (da)	2021-05-17	Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
KR20180084939A (ko)	2018-07-25	유체 중 피분석물의 광학 검출을 위한 다공성 미러
DK3370828T3 (da)	2020-07-13	Oximforbindelse som agonister af muscarin m1- og/eller m4- receptoren
DK3127300T3 (da)	2019-10-07	Håndtering af nic-krypterede flows til at migrere gæster eller opgaver
DK3197472T3 (da)	2021-10-18	Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3558278T3 (da)	2021-08-09	Flydende cannabinoidsammensætning
DK3532029T3 (da)	2021-06-07	Flydende farmaceutisk sammensætning
DK3014279T3 (da)	2023-01-09	Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida
DK3198284T3 (da)	2022-05-09	Paletbaserede systemer til analytkarakterisering
DK3484332T3 (da)	2022-10-24	Anordning til opnåelse af æggevæske
DK3535050T3 (da)	2022-06-27	Væskeblandingssystem med vertikalt justerbart blandeelement samt anvendelsesfremgangsmåde
DK3554501T3 (da)	2021-07-19	Dexmedetomidin eller medetomidin til anvendelse i behandling af separationsangst hos kæledyr
MA52595A (fr)	2021-03-17	Formulation liquide stable de gonadotrophines
DK3534002T3 (da)	2021-04-06	Væskepumpe
DK3330267T3 (da)	2022-03-14	Salt af quinazolinderivat eller crystal deraf samt fremgangsmåde til fremstilling af salt af quinazolinderivat eller crystal deraf
DK3339750T3 (da)	2020-09-21	Fluidforsynings- og cirkulationssystem
ES1187335Y (es)	2017-10-02	Pipeta de sujecion de ovocitos en procedimientos de inyeccion espermatica intracitoplasmatica
DE102014226681A8 (de)	2016-08-04	Flüssige Tensidzusammensetzung mit spezieller Tensidkombination und Enzym
DK3742164T3 (da)	2022-02-21	Indretning til bestemmelse af tilstedeværelsen og/eller mængden af målmolekyler
DK3449008T3 (da)	2021-12-06	In vitro-fremgangsmåde til identificering af bugspytkirtelkræft eller intraduktal papillær mucinøs neoplasma i bugspytkirtlen
DK3380487T3 (da)	2020-12-07	Additivsystemer til anvendelse i proteinpegylering
DK3149163T3 (da)	2020-08-31	Prohæmostatiske proteiner til behandling af blødning
DK3704328T3 (da)	2022-02-21	Flydende gulv
MA39921A (fr)	2021-06-02	Systèmes pour la détection d'anomalies sous-tissulaires